Genprex (NASDAQ:GNPX) Trading Up 3.8% – Should You Buy?

Genprex (NASDAQ:GNPX)’s stock price was up 3.8% during mid-day trading on Monday . The stock traded as high as $0.6854 and last traded at $0.6710. Approximately 192,953 shares were traded during trading, a decline of 23% from the average daily volume of 249,396 shares. The stock had previously closed at $0.6467.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on GNPX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a report on Tuesday, April 21st. Wall Street Zen raised shares of Genprex from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Genprex has an average rating of “Sell”.

Genprex Price Performance

The firm has a market cap of $7.11 million, a P/E ratio of -0.05 and a beta of -0.98. The stock’s 50 day moving average is $1.04 and its two-hundred day moving average is $1.88.

Genprex (NASDAQ:GNPX) last posted its earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter.

Hedge Funds Weigh In On Genprex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP lifted its position in shares of Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after purchasing an additional 35,661 shares in the last quarter. Manchester Financial Inc. acquired a new position in shares of Genprex during the first quarter worth approximately $36,000. Finally, Mayflower Financial Advisors LLC acquired a new position in shares of Genprex during the first quarter worth approximately $36,000. 14.05% of the stock is currently owned by institutional investors and hedge funds.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.